BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21495929)

  • 1. Salvage therapy for relapsed chronic lymphocytic leukemia.
    Andritsos LA; Grever MR
    Expert Rev Hematol; 2011 Apr; 4(2):199-212. PubMed ID: 21495929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Conventional therapeutic strategies for relapsed chronic lymphocytic leukemia].
    Guièze R; Ysebaert L; de Guibert S; Dhédin N; Bay JO; Troussard X; Tournilhac O
    Bull Cancer; 2012 Dec; 99(12):1123-32. PubMed ID: 23249977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the diagnosis and treatment of chronic lymphocytic leukemia.
    Abbott BL
    Hematol Oncol; 2005 Mar; 23(1):34-40. PubMed ID: 16149106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Ilaria Del Principe M; Buccisano F; Maurillo L; Niscola P; Venditti A; Amadori S
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1787-800. PubMed ID: 17181492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the diagnosis and treatment of chronic lymphocytic leukemia.
    Abbott BL
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):448-54. PubMed ID: 16163221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic lymphocytic leukemia].
    Wendtner CM
    Dtsch Med Wochenschr; 2012 Jun; 137(22):1162-5. PubMed ID: 22619012
    [No Abstract]   [Full Text] [Related]  

  • 8. Monoclonal antibodies in chronic lymphocytic leukemia.
    Ferrajoli A; Faderl S; Keating MJ
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1231-8. PubMed ID: 17020457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in chronic lymphocytic leukemia.
    Abbott BL
    Cancer Invest; 2006; 24(3):302-9. PubMed ID: 16809159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current strategies for treatment of relapsed/refractory multiple myeloma.
    Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
    Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
    Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):116-23. PubMed ID: 17222760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging therapeutic options for B-cell disorders: idiopathic thrombocytopenic purpura and chronic lymphocytic leukemia.
    Goodrich A
    Clin J Oncol Nurs; 2007 Feb; 11(1 Suppl):23-36. PubMed ID: 17474175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic lymphocytic leukemia: recent advances in diagnosis and treatment.
    Abbott BL
    Oncologist; 2006 Jan; 11(1):21-30. PubMed ID: 16401710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of hematopoietic stem cell transplantation in Chronic Lymphocytic Leukemia.
    Banerji V; Johnston JB; Seftel MD
    Transfus Apher Sci; 2007 Aug; 37(1):57-62. PubMed ID: 17919979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
    Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revisiting the role of hematopoietic stem cell transplantation in chronic lymphocytic leukemia.
    Santos ES; Masri M; Safah H
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):875-91. PubMed ID: 16221057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation.
    Bug G; Atta J; Klein SA; Hertenstein B; Bergmann L; Boehrer S; Mousset S; Hoelzer D; Martin H
    Ann Hematol; 2005 Oct; 84(11):748-54. PubMed ID: 16001243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.